Reduction of tertiary amine N-oxide by purified cytochrome P-450

doi:10.1016/S0006-291X(77)80098-3

Biochemical and Biophysical Research Communications

Volume 77, Issue 4, 22 August 1977, Pages 1143-1149

https://doi.org/10.1016/S0006-291X(77)80098-3 Get rights and content

Summary

A reconstituted system containing cytochrome P-450 and NADPH-cytochrome c reductase, purified from phenobarbital-induced rabbit and rat liver microsomes, respectively, catalyzed anaerobic reduction of tiaramide N-oxide by NADPH at a rate comparable to that observed with intact rabbit liver microsomes. The reduction was inhibited by oxygen and carbon monoxide. When reduced methyl viologen was used as electron donor, the reduction proceeded at a much higher rate in the absence of NADPH-cytochrome c reductase. Preparations of various species of cytochrome P-450 purified from rabbit and rat liver microsomes and camphor-grown Pseudomonas putida exhibited nearly the same N-oxide reducing activity with reduced methyl viologen as donor despite their widely different specificities for hydroxylatable substrates.

References (20)

SugiuraM. et al.
Life Sci.
(1974)
ImaiY. et al.
Biochem. Biophys. Res. Comm.
(1974)
HashimotoC. et al.
Biochem. Biophys. Res. Comm.
(1976)
HaugenD.A. et al.
J. Biol. Chem.
(1976)
YuC-A. et al.
J. Biol. Chem.
(1974)
PetersonJ.A.
Arch. Biochem. Biophys.
(1971)
OmuraT. et al.
J. Biol. Chem.
(1964)
KatoR. et al.
Biochem. Biophys. Res. Comm.
(1976)
NordblomG.D. et al.
Arch. Biochem. Biophys.
(1976)
PetersonJ.A. et al.
Arch. Biochem. Biophys.
(1972)

There are more references available in the full text version of this article.

Cited by (24)

Tamoxifen metabolism by microsomal cytochrome P450 and flavin-containing monooxygenase
1996, Methods in Enzymology
This chapter discusses the metabolism of tamoxifen by microsomal cytochrome P450 as well as flavin-containing monooxygenase. Tamoxifen (tam) is an antiestrogen and is developed as a therapeutic agent for hormone responsive (estrogen receptor-positive) breast tumors. Tamoxifen is metabolized by liver microsomes from animals and humans into a variety of compounds, such as tamoxifen N-oxide (tam- N-oxide), N-desmethyl (N-desmethyl-tam), and 4-hydroxy (4-OH-tam) derivatives. Microsomal CYP3A catalyzes covalent binding of tamoxifen to proteins and tam-N-demethylation. This chapter describes the radiometric methods developed for detection, identification, and quantitation of several of the major tamoxifen metabolites. The chapter also describes the hepatic enzymes forming these tamoxifen metabolites. The amount of N-oxide observed in incubations of tamoxifen with liver microsomes represents the net result of the flavin-containing monooxygenase (FMO)-catalyzed N-oxide formation (forward reaction) and the N-oxide reduction (reverse reaction).
Reduction of tertiary amine N-oxides by liver preparations: Function of aldehyde oxidase as a major N-oxide reductase
1984, Biochemical and Biophysical Research Communications
Reduction of tertiary amine N-oxides to the corresponding amines by liver preparations was investigated with imipramine N-oxide and cyclobenzaprine N-oxide under anaerobic conditions. Rabbit liver cytosol in the presence of an electron donor of aldehyde oxidase exhibited a significant N-oxide reductase activity which is comparable to the activity of the liver microsomes supplemented with NADPH. Rabbit liver aldehyde oxidase also exhibited the N-oxide reductase activity in the presence of its electron donor, indicating that the activity observed in the liver cytosol is due to this cytosolic enzyme. Furthermore, the tertiary amine N-oxide reductase activity of liver cytosols from rats, mice, hamsters and hogs was demonstrated by comparison with that of liver microsomes from these mammalian species.
A heme model system for the reduction of substrates by microsomal cytochrome P 450
1982, Biochemical and Biophysical Research Communications
A biphasic (H₂O-toluene) system using sodium ascorbate as a reducing agent and an iron-porphyrin as a catalyst, is able to quantitatively reduce several substrates such as halogenated compounds, arene-oxides, nitro- and nitroso-aromatics at room temperature, even in the presence of dioxygen. It only works thanks to a double catalysis, that of ascorbate transfer to the organic phase by a phase transfer agent and that of the electron transfer to the substrate by the iron-porphyrin. It is able to perform most of the cytochrome P450-dependent microsomal reductions of substrates with very similar products patterns and rates, indicating that it can be used to mimic and study the microsomal reductions of substrates by cytochrome P450.
Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates
1980, Biochemical Pharmacology
The metabolism of the hallucinogen N,N-dimethyltryptamine (DMT) in whole rat brain homogenate is reported. Studies were conducted using tritiated DMT and DMT-N-oxide (DMT-NO), and metabolites were identified and quantified using thin-layer chromatography and liquid scintillation counting techniques. Metabolite confirmation was obtained by incubation of α,α,β,β-tetradeutero-DMT (DDMT) with whole brain homogenate followed by combined gas chromatographic/mass spectrometric analyses. The metabolites of DMT were identified as indoleacetic acid (IAA), DMT-NO, N-methyltryptamine (NMT), 2-methyl-1,2,3,4-tetrahydro-β-carboline (2-MTHBC), tryptamine (TA) and 1,2,3,4- tetrahydro-β-carboline (THBC). DMT-NO was metabolized to give DMT, NMT, IAA and 2-MTHBC. Formation of these metabolites from DMT-NO was stimulated by anaerobic incubation. Mechanisms for the formation of β-carbolines from DMT and DMT-NO are discussed. The effects of the monamine oxidase inhibitor iproniazid phosphate on DMT metabolism were also studied. Iproniazid inhibited the formation of IAA from DMT by 83 per cent. However, the formation of NMT and DMT-NO was inhibited by 90 per cent under these conditions. Thus, the reported extension of half-life and potentiation of DMT behavioral effects by iproniazid may be due to inhibition of NMT and DMT-NO formation rather than inhibition of monoamine oxidase. A cyclic pathway for the synthesis and metabolism of DMT in brain tissue is proposed.
Reduction of N-hydroxy-2-acetylaminofluorene by liver microsomes
1980, Biochemical Pharmacology
The reduction of N-hydroxy-2-acetylaminofluorene(N-hydroxy-AAF) to 2-acetylamino-fluorene and 2-aminofluorene by liver microsomes was studied. The reductase preferred NADPH rather than NADH as a cofactor and was strongly inhibited by carbon monoxide and oxygen. Further, the inhibitors of hepatic mixed function oxidase effectively inhibited the reductase activity. Pretreatments of rats with 3-methylcholanthrene and PCB markedly induced the reductase activity. From these results it was suggested that the reduction of N-hydroxy-AAF was catalysed by cytochrome P-450, especially by cytochrome P-448. The reductase activity was also detected in microsomes from lung, kidney and small intestinal mucosa, and the rates of the reduction were about 6, 7 and 27 per cent, respectively, of that in liver microsomes. Species difference in the reductase activity of liver microsomes was also examined. The highest activity of the reductase was found in hamsters, followed by guinea pigs and rabbits.
Stoichiometry of the mixed function oxidase
1979, Pharmacology and Therapeutics

View all citing articles on Scopus

^*: Present address: Department of Pharmacology, School of Medicine, Keio University, Shinanomachi, Shinjuku-ku, Tokyo 160, Japan

View full text

Reduction of tertiary amine N-oxide by purified cytochrome P-450

Summary

Life Sci.

Biochem. Biophys. Res. Comm.

Biochem. Biophys. Res. Comm.

J. Biol. Chem.

J. Biol. Chem.

Arch. Biochem. Biophys.

J. Biol. Chem.

Biochem. Biophys. Res. Comm.

Arch. Biochem. Biophys.

Arch. Biochem. Biophys.